$374 Million is the total value of VHCP Management II, LLC's 21 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ECYT | Sell | Endocyte Inc | $74,793,000 | +26.0% | 4,211,302 | -2.1% | 19.97% | +12.4% |
| BHVN | Biohaven Pharmaceuticals | $53,148,000 | -5.0% | 1,415,391 | 0.0% | 14.19% | -15.2% | |
| OBSV | Obseva SA | $40,612,000 | +19.1% | 2,252,460 | 0.0% | 10.84% | +6.2% | |
| ASND | Ascendis Pharma A/S | $35,728,000 | +6.5% | 504,210 | 0.0% | 9.54% | -5.0% | |
| TCDA | Tricida Inc | $29,410,000 | +2.2% | 962,696 | 0.0% | 7.85% | -8.8% | |
| BCRX | Buy | BioCryst Pharmaceuticals Inc | $24,791,000 | +75.6% | 3,249,164 | +31.9% | 6.62% | +56.6% |
| ZGNX | Zogenix | $17,956,000 | +12.2% | 362,010 | 0.0% | 4.80% | +0.1% | |
| KALV | New | Kalvista Pharmaceuticals | $16,785,000 | – | 759,181 | +100.0% | 4.48% | – |
| KNSA | Kiniksa Pharmaceuticals Ltd | $16,300,000 | +47.0% | 639,230 | 0.0% | 4.35% | +31.1% | |
| DBVT | DBV Technologies | $14,084,000 | +17.1% | 463,149 | 0.0% | 3.76% | +4.4% | |
| RARX | Ra Pharmaceuticals | $9,852,000 | +81.8% | 544,612 | 0.0% | 2.63% | +62.2% | |
| ARGX | Sell | Argenx | $9,185,000 | -68.3% | 121,581 | -64.9% | 2.45% | -71.7% |
| MNTA | Sell | Momenta Pharmaceuticals | $6,912,000 | -20.5% | 262,822 | -38.2% | 1.85% | -29.0% |
| SPRO | Spero Therapeutics Inc | $4,982,000 | -28.4% | 474,015 | 0.0% | 1.33% | -36.1% | |
| CNST | New | Constellation Pharmaceuticals | $4,891,000 | – | 726,677 | +100.0% | 1.31% | – |
| KDMN | Kadmon Holdings Inc. | $4,714,000 | -16.3% | 1,411,428 | 0.0% | 1.26% | -25.3% | |
| BLPH | Bellerophon Therapeutics | $4,481,000 | -55.4% | 4,149,378 | 0.0% | 1.20% | -60.2% | |
| MRNS | Buy | Marinus Pharmaceuticals Inc | $3,972,000 | +62.7% | 397,236 | +15.1% | 1.06% | +45.1% |
| GEMP | New | Gemphire Therapeutics | $1,058,000 | – | 513,752 | +100.0% | 0.28% | – |
| APLS | Apellis Pharmaceuticals Inc | $528,000 | -19.3% | 29,710 | 0.0% | 0.14% | -28.1% | |
| CCXI | ChemoCentryx Inc | $292,000 | -3.9% | 23,064 | 0.0% | 0.08% | -14.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Ascendis Pharma A/S | 16 | Q3 2019 | 18.3% |
| BioCryst Pharmaceuticals Inc | 15 | Q3 2019 | 20.9% |
| Ra Pharmaceuticals | 12 | Q3 2019 | 6.4% |
| Biohaven Pharmaceuticals | 11 | Q4 2019 | 18.1% |
| Obseva SA | 11 | Q4 2019 | 12.2% |
| DBV Technologies | 10 | Q1 2018 | 11.6% |
| Kalvista Pharmaceuticals | 10 | Q4 2019 | 6.4% |
| Bellerophon Therapeutics | 10 | Q4 2019 | 3.0% |
| AveXis Inc | 9 | Q1 2018 | 32.2% |
| Edge Therapeutics Inc | 9 | Q4 2017 | 18.2% |
View VHCP Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-10-26 |
| 4 | 2022-10-20 |
| 4 | 2022-10-17 |
| 4 | 2022-10-11 |
| 4 | 2022-10-06 |
| 4 | 2022-10-03 |
| 4 | 2022-09-28 |
| 4 | 2022-09-07 |
| 4 | 2022-09-01 |
| 4 | 2022-08-02 |
View VHCP Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.